SCHEMBL933856

SCHEMBL933856

C(=C/C1CCCCC1)\c1ccccc1

nearest known ligand 0.63

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
MAOA P21397 2/20 0.51
MAOB P27338 1/20 0.51
KDM1A O60341 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL164340 1.00 MAOA (0.51) MAOAMAOBKDM1A
SCHEMBL24198614 0.98 MAOA (0.53) MAOAMAOBKDM1A
SCHEMBL18616933 0.93 MAOA (0.53) MAOAMAOBKDM1A
SCHEMBL9539801 0.89 MAOA (0.56) MAOAMAOBKDM1A
SCHEMBL1610007 0.89 MAOA (0.56) MAOAMAOBKDM1A
SCHEMBL29168417 0.88 ALDH1A1 (0.44) MAOAMAOB
SCHEMBL4203195 0.79 NPC1 (0.41)
SCHEMBL20015683 0.79 KDM1A (0.51) MAOAMAOBKDM1A
SCHEMBL30987469 0.79 MAOB (0.54) MAOAMAOB
SCHEMBL818902 0.79 KDM1A (0.51) MAOAMAOBKDM1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9765054-B2 Histone deacetylase inhibitors and compositions and methods of use thereof CHDI FOUNDATION, INC. (US) 2017-09-19 US disclosed
US-20150191607-A1 Anti-fouling Paints and Coatings REACTIVE SURFACES, LTD (US) 2015-07-09 US disclosed
US-20140163009-A1 HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF CHDI Foundation (US) 2014-06-12 US disclosed
EP-2667709-A1 HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF CHDI Foundation, Inc. (US) 2013-12-04 EP disclosed
US-20120238740-A1 NON-POLAR AND POLAR LEAVING GROUPS BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2012-09-20 US disclosed
WO-2012103008-A1 HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF CHDI FOUNDATION, INC. (US) 2012-08-02 WO disclosed
EP-2454216-A1 NON-POLAR AND POLAR LEAVING GROUPS Bayer Pharma Aktiengesellschaft (DE) 2012-05-23 EP disclosed
CN-102471176-A Non-polar and polar leaving groups BAYER SCHERING PHARMA AG 2012-05-23 CN disclosed
WO-2011006610-A1 NON-POLAR AND POLAR LEAVING GROUPS BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2011-01-20 WO disclosed
US-6900273-B1 Low-hygroscopicity low-birefringence resin compositions, molding material obtained therefrom, sheet or film, and optical part HITACHI CHEMICAL CO., LTD. (JP) 2005-05-31 US disclosed
US-20040220342-A1 Low-hygroscopicity low-birefringence resin compositions, molding material, sheet or film obtained therefrom, and optical part YAMASHITA YUKIHIKO (JP) 2004-11-04 US disclosed
EP-1205517-A1 LOW-HYGROSCOPICITY LOW-BIREFRINGENCE RESIN COMPOSITIONS, MOLDING MATERIAL OBTAINED THEREFROM, SHEET OR FILM, AND OPTICAL PART HITACHI CHEMICAL COMPANY, LTD. (JP) 2002-05-15 EP disclosed
US-5476611-A Polymer dispersed liquid crystal MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 1995-12-19 US disclosed
US-3946081-A OXIDATION CATALYSTS, GROUP V, VI, OR VII OXIDES BAYER AKTIENGESELLSCHAFT (DT) 1976-03-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120238740-A1 NON-POLAR AND POLAR LEAVING GROUPS PGLS, RABGGTB, LNPEP MAOA 569/4885MAOB 399/4885KDM1A 3554/4885
US-20140163009-A1 HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF HDAC1, HDAC7, HDAC5 MAOA 455/4885MAOB 362/4885KDM1A 36/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.